Q-omics provides the consensus-scored ACTR1B profile across patient tissues and cancer cell-line models. ACTR1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ACTR1B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ACTR1B protein abundance shows 29,221 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where ACTR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTR1B survival associations across molecular data types. ACTR1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTR1B RNA expression–survival associations across cancer types. High ACTR1B expression shows unfavorable associations in ACC, UVM, LAML and LIHC, but favorable associations in ESCA and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ACTR1B RNA expression.
This table summarizes ACTR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ACTR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTR1B shows lower tumor expression in KICH, LUAD and BRCA and higher tumor expression in COAD, LIHC and KIRC. The COAD box plot shows higher ACTR1B RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with ACTR1B in patient tissues and cancer cell lines. In patient samples, ACTR1B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
